#1 Clinical Trials Search in Europe

Dapirolizumab Pegol

Dapirolizumab Pegol (DZP) is an investigational drug being studied for the treatment of Systemic Lupus Erythematosus (SLE), a complex autoimmune disease. Clinical trials are underway to assess its safety, efficacy, and long-term effects in patients with moderate to severe SLE. These studies aim to determine the optimal dosing, evaluate potential side effects, and measure improvements in disease activity and quality of life for lupus patients.

Table of Contents

What is Dapirolizumab Pegol?

Dapirolizumab Pegol, also known as DZP, BIIB133, or CDP7657, is a new medication being studied for the treatment of autoimmune diseases, particularly Systemic Lupus Erythematosus (SLE)[1]. It is an innovative drug that belongs to a class of medications called biologics, which are designed to target specific parts of the immune system[2].

What Conditions Does It Treat?

The primary focus of research for Dapirolizumab Pegol is its potential to treat Systemic Lupus Erythematosus (SLE). SLE is a complex autoimmune disease where the body’s immune system mistakenly attacks healthy tissues, causing inflammation and damage to various parts of the body, including the skin, joints, kidneys, brain, and other organs[1][2].

How Does It Work?

While the exact mechanism of action is not fully described in the provided clinical trial information, biologics like Dapirolizumab Pegol typically work by targeting specific components of the immune system. In the case of SLE, the drug likely aims to reduce the abnormal immune response that causes inflammation and tissue damage[2].

Clinical Trials and Research

Dapirolizumab Pegol is currently undergoing extensive clinical research to evaluate its effectiveness and safety. Several clinical trials are being conducted:

  • A long-term safety and tolerability study for patients with SLE[1].
  • A Phase 2 study to assess the efficacy and safety of different doses in patients with moderately to severely active SLE[2].
  • A Phase 1 study to evaluate the drug’s characteristics in healthy Japanese and Caucasian participants[3].

These trials are examining various aspects of the drug, including:

  • Efficacy: Researchers are using specific measures to determine how well the drug works in controlling SLE symptoms and disease activity. For example, they’re looking at the BILAG-based Composite Lupus Assessment (BICLA) response, which is a comprehensive way to evaluate improvement in lupus symptoms[2].
  • Safety: The studies are closely monitoring for any side effects or adverse events that may occur during treatment[1][2][3].
  • Dosing: Different doses of the medication are being tested to find the most effective and safe amount[2].
  • Long-term effects: Some studies are designed to assess the long-term safety and effectiveness of the drug[1].

Safety and Side Effects

As with any medication, safety is a crucial aspect of the research on Dapirolizumab Pegol. The clinical trials are carefully monitoring for any adverse events (side effects) that may occur. Some of the specific safety concerns being evaluated include:

  • Infections: Researchers are watching for moderate to severe infections, including opportunistic infections and tuberculosis[2].
  • Infusion reactions: As the drug is given intravenously, there’s a potential for reactions during or after the infusion[2].
  • Thromboembolic events: This includes monitoring for blood clots that could lead to serious conditions like heart attacks or strokes[2].
  • Neurological events: Researchers are paying attention to any severe headaches or other neurological symptoms[2].
  • Malignancies: As with many medications that affect the immune system, there’s a need to monitor for any potential increased risk of cancer[2].

It’s important to note that these are potential risks being monitored in the clinical trials, and not all patients will experience these side effects. The purpose of these studies is to thoroughly evaluate the safety profile of the drug before it becomes widely available[1][2][3].

Administration

Based on the information from the clinical trials, Dapirolizumab Pegol is administered through intravenous (IV) infusion. This means the medication is given directly into a vein. The dosing schedule and amount can vary depending on the specific study protocol[2][3].

It’s important to understand that Dapirolizumab Pegol is still in the research phase and is not yet approved for general use. Patients interested in this treatment should discuss with their healthcare providers about the possibility of participating in clinical trials or about other currently available treatments for SLE[1][2][3].

Aspect Details
Drug Name Dapirolizumab Pegol (DZP)
Condition Studied Systemic Lupus Erythematosus (SLE)
Trial Phases Phase 1 and Phase 2
Primary Objectives Evaluate safety, tolerability, and efficacy
Key Outcome Measures BICLA response, prevention of severe flares, adverse events
Study Duration Up to 104 weeks or longer
Administration Intravenous infusion
Population Adults with moderate to severe SLE

FAQ

  • What is Dapirolizumab Pegol? Dapirolizumab Pegol (DZP) is an experimental medication being studied for the treatment of Systemic Lupus Erythematosus (SLE). It is designed to target specific components of the immune system involved in lupus.
  • What is the main purpose of the clinical trials for Dapirolizumab Pegol? The main purposes of the clinical trials are to evaluate the safety, tolerability, and effectiveness of Dapirolizumab Pegol in patients with moderate to severe Systemic Lupus Erythematosus. The studies also aim to determine the best dosing regimen and assess long-term effects of the treatment.
  • How is the effectiveness of Dapirolizumab Pegol measured in these trials? The effectiveness is measured using various assessment tools, including the BILAG-based Composite Lupus Assessment (BICLA) response, which looks at improvements in disease activity across different organ systems. Other measures include prevention of severe flares and achievement of low disease activity states.
  • What are some of the potential side effects being monitored in these trials? The trials are monitoring for various side effects, including but not limited to infections, infusion reactions, thromboembolic events, neurological events, and changes in laboratory values such as blood cell counts and liver function tests.
  • How long do these clinical trials typically last? The duration of the trials varies, but many extend up to 104 weeks (2 years) or longer. This includes treatment periods and follow-up assessments to evaluate long-term safety and efficacy of Dapirolizumab Pegol.

Ongoing Clinical Trials on Dapirolizumab Pegol

  • Study on the Effectiveness and Safety of Dapirolizumab Pegol for Patients with Moderate to Severe Systemic Lupus Erythematosus

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Denmark France Germany Greece Italy +3

  • Study on the Long-Term Safety of Dapirolizumab Pegol for Patients with Systemic Lupus Erythematosus

    Recruiting

    3 1 1 1
    Investigated drugs:
    Belgium Bulgaria Czechia Denmark France Germany +7

Glossary

  • Systemic Lupus Erythematosus (SLE): A chronic autoimmune disease that can affect various parts of the body, including skin, joints, kidneys, brain, and other organs.
  • BILAG-based Composite Lupus Assessment (BICLA): A tool used to measure the response to treatment in lupus patients, assessing improvement across different organ systems affected by the disease.
  • Dapirolizumab Pegol (DZP): An investigational drug being studied for the treatment of moderate to severe Systemic Lupus Erythematosus.
  • Placebo: An inactive substance used in clinical trials to compare the effects of a drug against no treatment.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Serious Adverse Event (SAE): An adverse event that results in death, is life-threatening, requires hospitalization, causes persistent disability, or is otherwise medically significant.
  • SLEDAI-2K: Systemic Lupus Erythematosus Disease Activity Index 2000, a tool used to measure disease activity in lupus patients.
  • Physician's Global Assessment (PGA): A measure of overall disease activity as assessed by a physician, often using a visual analog scale.
  • Immunogenicity: The ability of a substance to provoke an immune response in the body, which is important to assess for biological drugs.

References

  1. https://clinicaltrials.eu/trial/study-on-the-long-term-safety-of-dapirolizumab-pegol-for-patients-with-systemic-lupus-erythematosus/
  2. https://clinicaltrials.gov/study/NCT02804763
  3. https://clinicaltrials.gov/study/NCT04571424